mFOLFOX7 combined with Camrelizumab and apatinib
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma Non-resectable
Conditions
Hepatocellular Carcinoma Non-resectable
Trial Timeline
Feb 17, 2024 → Jan 11, 2028
NCT ID
NCT06607107About mFOLFOX7 combined with Camrelizumab and apatinib
mFOLFOX7 combined with Camrelizumab and apatinib is a phase 2 stage product being developed by Sun Pharmaceutical for Hepatocellular Carcinoma Non-resectable. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06607107. Target conditions include Hepatocellular Carcinoma Non-resectable.
What happened to similar drugs?
5 of 20 similar drugs in Hepatocellular Carcinoma Non-resectable were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06607107 | Phase 2 | Recruiting |
Competing Products
20 competing products in Hepatocellular Carcinoma Non-resectable